Use of New Techniques in Addition to IHC Applied to the Diagnosis of Melanocytic Lesions, With Emphasis on CGH, FISH, and Mass Spectrometry

Nagarajan, Priyadharsini; Tetzlaff, Michael T.; Curry, Jonathan L.; Prieto, Víctor G.

doi:10.1016/j.ad.2016.05.005

Cited by 12 publications

(6 citation statements)

References 150 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The scoring algorithm assigns samples with a score ≥0.85 as "melanoma," samples with a score ≤0.15 as "benign," and samples with scores >0. 15 1 in Supplementary Material).…”

Section: Resultsmentioning

confidence: 99%

“…Assays based on comparative genomic hybridization (CGH), gene expression profiles, and fluorescence in situ hybridization (FISH) are among the recently developed laboratory tests for this specific purpose. [13][14][15][16][17] Matrix-assisted laser desorption ionization imaging mass spectrometry (MALDI IMS) is a technology ideal for providing proteomics information supporting the pathologist's diagnosis. In a MALDI IMS experiment, thin tissue sections are prepared similarly to traditional histopathological experiments and analyzed using a MALDI mass spectrometer.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Diagnosis of melanoma by imaging mass spectrometry: Development and validation of a melanoma prediction model

et al. 2021

View full text Add to dashboard Cite

Background: The definitive diagnosis of melanocytic neoplasia using solely histopathologic evaluation can be challenging. Novel techniques that objectively confirm diagnoses are needed. This study details the development and validation of a melanoma prediction model from spatially resolved multivariate protein expression profiles generated by imaging mass spectrometry (IMS). Methods: Three board-certified dermatopathologists blindly evaluated 333 samples. Samples with triply concordant diagnoses were included in this study, divided into a training set (n = 241) and a test set (n = 92). Both the training and test sets included various representative subclasses of unambiguous nevi and melanomas. A prediction model was developed from the training set using a linear support vector machine classification model. Results:We validated the prediction model on the independent test set of 92 specimens (75 classified correctly, 2 misclassified, and 15 indeterminate). IMS detects melanoma with a sensitivity of 97.6% and a specificity of 96.4% when evaluating each unique spot. IMS predicts melanoma at the sample level with a sensitivity of 97.3% and a specificity of 97.5%. Indeterminate results were excluded from sensitivity and specificity calculations. Conclusion:This study provides evidence that IMS-based proteomics results are highly concordant to diagnostic results obtained by careful histopathologic evaluation from a panel of expert dermatopathologists.

show abstract

“…The scoring algorithm assigns samples with a score ≥0.85 as "melanoma," samples with a score ≤0.15 as "benign," and samples with scores >0. 15 1 in Supplementary Material).…”

Section: Resultsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Diagnosis of melanoma by imaging mass spectrometry: Development and validation of a melanoma prediction model

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Ki-67 is a proliferation marker that is expressed in all cell cycle phases (G1, S, M, and G2), but not in G0; it can identify all cycling cells [ 50 ]. Increased Ki-67 has been correlated with recurrence and metastasis, especially in thick tumors [ 51 ].…”

Section: Resultsmentioning

confidence: 99%

Liposomes Loaded with Amaranth Unsaponifiable Matter and Soybean Lunasin Prevented Melanoma Tumor Development Overexpressing Caspase-3 in an In Vivo Model

et al. 2022

View full text Add to dashboard Cite

The objective of this study was to assess the effectiveness of liposomes loaded with soybean lunasin and amaranth unsaponifiable matter (UM + LunLip) as a source of squalene in the prevention of melanoma skin cancer in an allograft mice model. Tumors were induced by transplanting melanoma B16-F10 cells into the mice. The most effective treatments were those including UM + LunLip, with no difference between the lunasin concentrations (15 or 30 mg/kg body weight); however, these treatments were statistically different from the tumor-bearing untreated control (G3) (p < 0.05). The groups treated with topical application showed significant inhibition (68%, p < 0.05) compared to G3. The groups treated with subcutaneous injections showed significant inhibition (up to 99%, p < 0.05) in G3. During tumor development, UM + LunLip treatments under-expressed Ki-67 (0.2-fold compared to G3), glycogen synthase kinase-3β (0.1-fold compared to G3), and overexpressed caspase-3 (30-fold compared to G3). In addition, larger tumors showed larger necrotic areas (38% with respect to the total tumor) (p < 0.0001). In conclusion, the UM + LunLip treatment was effective when applied either subcutaneously or topically in the melanoma tumor-developing groups, as it slowed down cell proliferation and activated apoptosis.

show abstract

“…There have been recent reports regarding the utility of soluble adenylyl cyclase antibody (R21) as helpful in margin assessment for lentigo maligna . Newer molecular diagnostics such as comparative genomic hybridization and whole-genome sequencing represent an exciting and rapidly evolving field with potential for future breakthroughs enhancing personalized medicine, which are beyond the scope of this article …”

Section: Resultsmentioning

confidence: 99%

Contemporary Management of Early-Stage Melanoma

Rosko

VanKoevering

McLean

et al. 2017

JAMA Facial Plast Surg

View full text Add to dashboard Cite

he incidence of cutaneous melanoma has increased rapidly over the past 30 years. While melanoma only accounts for 1% of skin cancers, it is responsible for the majority of skin cancer deaths. 1 It is estimated that 76 380 new cases of invasive melanoma and 68 480 new cases of melanoma in situ will be diagnosed in 2016. 1 The lifetime risk of developing melanoma has reached 1 in 33 for men and 1 in 52 for women in 2016. 2 An estimated 10 130 Americans will die from melanoma in 2016. 2 Given the large burden of disease, there is substantial energy dedicated to melanoma research. While the most important recent advances in the treatment of melanoma have been in the management of advanced disease with targeted therapies and modulation of the immune system, this systematic review provides up-to-date data and high-level evidence to support the contemporary management of early-stage melanoma. MethodsWe performed a review of the PubMed, MEDLINE, and the Cochrane Database of Systematic Reviews databases using specific search strategies. Our primary search used the terms melanoma, melanoma in situ, lentigo maligna, and head and neck. We screened articles published between January 1, 2011, and May 1, 2016. Our ini-tial search of the 3 databases yielded 1202 articles. After excluding duplicates, there were 966 citations. We restricted articles to human data reported in the English language only, which excluded 252 articles. We focused our search on cutaneous melanoma, and thus articles on mucosal melanoma were excluded. We also focused our search on early-stage melanoma (melanoma in situ, stage I, and stage II), and thus articles only addressing advanced-stage melanomas were excluded. Additionally, we excluded opinion articles and commentaries. We selected only articles deemed to provide contemporary evidence and/or major advances in the diagnosis or treatment of early-stage melanoma of the head and neck. This yielded 41 articles, which were manually reviewed (Figure 1). A careful review of the bibliographies of selected articles generated additional references. Results Diagnosis BiopsyThe first step in managing cutaneous melanoma is establishing an accurate histopathological diagnosis. An incisional biopsy removes a portion of a lesion, whereas an excisional biopsy removes the entire clinically apparent lesion. Techniques for incisional and exci-IMPORTANCE The incidence of melanoma is increasing, with 76 380 new cases of invasive melanoma and 68 480 new cases of melanoma in situ expected in 2016.OBJECTIVE To review the contemporary management of early-stage melanoma.

show abstract

Use of New Techniques in Addition to IHC Applied to the Diagnosis of Melanocytic Lesions, With Emphasis on CGH, FISH, and Mass Spectrometry

Cited by 12 publications

References 150 publications

Diagnosis of melanoma by imaging mass spectrometry: Development and validation of a melanoma prediction model

Diagnosis of melanoma by imaging mass spectrometry: Development and validation of a melanoma prediction model

Liposomes Loaded with Amaranth Unsaponifiable Matter and Soybean Lunasin Prevented Melanoma Tumor Development Overexpressing Caspase-3 in an In Vivo Model

Contemporary Management of Early-Stage Melanoma

Contact Info

Product

Resources

About